JanOne Inc. (JAN)
Company Description
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction.
It operates through three segments: Biotechnology, Recycling, and Technology.
The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain.
It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services.
The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019.
JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

Country | United States |
IPO Date | Nov 7, 1991 |
Industry | Waste Management |
Sector | Industrials |
Employees | 5 |
CEO | Tony Isaac |
Contact Details
Address: 325 East Warm Springs Road Las Vegas, Nevada United States | |
Website | https://www.janone.com |
Stock Details
Ticker Symbol | JAN |
Exchange | NASDAQ |
Fiscal Year | February - January |
Reporting Currency | USD |
CIK Code | 0000862861 |
CUSIP Number | 47089W104 |
ISIN Number | US47089W1045 |
Employer ID | 41-1454591 |
SIC Code | 5700 |
Key Executives
Name | Position |
---|---|
Tony Isaac | President, Chief Executive Officer, Corporate Secretary, Treasurer & Director |
Virland A. Johnson CPA | Chief Financial Officer |
Dr. Douglas Flanagan | Chief Formulation Advisor |
Dr. Tony Giordano Ph.D. | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 31, 2025 | 8-K | Current Report |
Mar 28, 2025 | 10-K | Annual Report |
Mar 25, 2025 | 10-K/A | [Amend] Annual Report |
Feb 10, 2025 | 5 | Filing |
Dec 19, 2024 | 8-K | Current Report |
Dec 10, 2024 | 4 | Filing |
Nov 26, 2024 | 8-K | Current Report |
Nov 13, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 05, 2024 | DEF 14A | Filing |